High Annexin A5 expression promotes tumor progression and poor prognosis in renal cell carcinoma

Tang,Jingyuan; Qin,Zhiqiang; Han,Peng; Wang,Wei; Yang,Chengdi; Xu,Zhen; Li,Ran; Liu,Bianjiang; Qin,Chao; Wang,Zengjun; Tang,Min; Zhang,Wei

doi:10.3892/ijo.2017.3942

High Annexin A5 expression promotes tumor progression and poor prognosis in renal cell carcinoma

Authors:
- Jingyuan Tang
- Zhiqiang Qin
- Peng Han
- Wei Wang
- Chengdi Yang
- Zhen Xu
- Ran Li
- Bianjiang Liu
- Chao Qin
- Zengjun Wang
- Min Tang
- Wei Zhang
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China
Published online on: April 3, 2017 https://doi.org/10.3892/ijo.2017.3942
Pages: 1839-1847

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Annexin A5 has been found to act as an oncogenic protein in a variety of cancers. However, its specific biological role and mechanism in renal cell cancer (RCC) remains unknown. Quantitative Real-time PCR and western blotting were used to evaluate the mRNA and protein expression level of Annexin A5 in human RCC cell lines and tissues. Immunohistochemistry was adopted to measure the Annexin A5 expression in 123 cases of RCC tissues. Survival analysis was performed to explore the association between Annexin A5 expression and the prognosis of RCC. The effect of Annexin A5 on RCC growth and metastasis was studied in vitro and in vivo. Annexin A5 was frequently highly expressed in both human RCC cells and tissues. High Annexin A5 expression was associated with higher clinical stage and histological grade. In addition, Annexin A5 might be used as a predictive factor for the prognosis of RCC. Further research suggested that upregulated Annexin A5 in RCC cells could significantly promote tumor cell proliferation, migration and invasion in vitro. Subcutaneous xenograft tumor model displayed that knockdown of Annexin A5 could impede tumorigenesis in vivo. Moreover, mechanism study exhibited that Annexin A5 could activate PI3K/Akt/mTOR signaling pathway, promote epithelial-mesenchymal transition (EMT) and the expression of MMP2 and MMP9. Annexin A5 may be a potential prognostic biomarker in RCC and promotes proliferation, migration and invasion of RCC cells via activating PI3K/Akt/mTOR signaling pathway and regulating EMT process and MMP expression.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Yu W, Wang Y, Jiang Y, Zhang W and Li Y: Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review. Histopathology. Feb 15–2017.Epub ahead of print. View Article : Google Scholar
3	Golovastova MO, Korolev DO, Tsoy LV, Varshavsky VA, Xu WH, Vinarov AZ, Zernii EY, Philippov PP and Zamyatnin AA Jr: Biomarkers of renal tumors: The current state and clinical perspectives. Curr Urol Rep. 18:32017. View Article : Google Scholar : PubMed/NCBI
4	Choueiri TK and Motzer RJ: Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 376:354–366. 2017. View Article : Google Scholar : PubMed/NCBI
5	Mirsaeidi M, Gidfar S, Vu A and Schraufnagel D: Annexins family: Insights into their functions and potential role in pathogenesis of sarcoidosis. J Transl Med. 14:892016. View Article : Google Scholar : PubMed/NCBI
6	Laohavisit A and Davies JM: Annexins. New Phytol. 189:40–53. 2011. View Article : Google Scholar
7	Bouter A, Carmeille R, Gounou C, Bouvet F, Degrelle SA, Evain-Brion D and Brisson AR: Review: Annexin-A5 and cell membrane repair. Placenta. 36(Suppl 1): S43–S49. 2015. View Article : Google Scholar : PubMed/NCBI
8	Lauritzen SP, Boye TL and Nylandsted J: Annexins are instrumental for efficient plasma membrane repair in cancer cells. Semin Cell Dev Biol. 45:32–38. 2015. View Article : Google Scholar : PubMed/NCBI
9	Fatimathas L and Moss SE: Annexins as disease modifiers. Histol Histopathol. 25:527–532. 2010.PubMed/NCBI
10	Mussunoor S and Murray GI: The role of annexins in tumour development and progression. J Pathol. 216:131–140. 2008. View Article : Google Scholar : PubMed/NCBI
11	Gerke V, Creutz CE and Moss SE: Annexins: Linking Ca²⁺ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 6:449–461. 2005. View Article : Google Scholar : PubMed/NCBI
12	Rescher U and Gerke V: Annexins - unique membrane binding proteins with diverse functions. J Cell Sci. 117:2631–2639. 2004. View Article : Google Scholar : PubMed/NCBI
13	Hayes MJ and Moss SE: Annexins and disease. Biochem Biophys Res Commun. 322:1166–1170. 2004. View Article : Google Scholar : PubMed/NCBI
14	Peng B, Guo C, Guan H, Liu S and Sun MZ: Annexin A5 as a potential marker in tumors. Clin Chim Acta. 427:42–48. 2014. View Article : Google Scholar
15	Guo W, Xue J, Shi J, Li N, Shao Y, Yu X, Shen F, Wu M, Liu S and Cheng S: Proteomics analysis of distinct portal vein tumor thrombi in hepatocellular carcinoma patients. J Proteome Res. 9:4170–4175. 2010. View Article : Google Scholar : PubMed/NCBI
16	Cojocaru E, Lozneanu L, Giuşcă SE, Căruntu ID and Danciu M: Renal carcinogenesis - insights into signaling pathways. Rom J Morphol Embryol. 56:15–19. 2015.
17	Hong M, Park N and Chun YJ: Role of annexin a5 on mitochondria-dependent apoptosis induced by tetramethoxystilbene in human breast cancer cells. Biomol Ther (Seoul). 22:519–524. 2014. View Article : Google Scholar
18	Bae SM, Lee CH, Cho YL, Nam KH, Kim YW, Kim CK, Han BD, Lee YJ, Chun HJ and Ahn WS: Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecol Oncol. 99:26–35. 2005. View Article : Google Scholar : PubMed/NCBI
19	Xue G, Hao LQ, Ding FX, Mei Q, Huang JJ, Fu CG, Yan HL and Sun SH: Expression of Annexin A5 is associated with higher tumor stage and poor prognosis in colorectal adenocarcinomas. J Clin Gastroenterol. 43:831–837. 2009. View Article : Google Scholar : PubMed/NCBI
20	Rajcevic U, Petersen K, Knol JC, Loos M, Bougnaud S, Klychnikov O, Li KW, Pham TV, Wang J, Miletic H, et al: iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics. 8:2595–2612. 2009. View Article : Google Scholar : PubMed/NCBI
21	Sofiadis A, Becker S, Hellman U, Hultin-Rosenberg L, Dinets A, Hulchiy M, Zedenius J, Wallin G, Foukakis T, Hoog A, et al: Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol. 166:657–667. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wang J, Zhang Y, Liu X, Ma J, Liu P, Hu C and Zhang G: Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling. Oncol Rep. 32:2557–2563. 2014.PubMed/NCBI
23	Yu JS and Cui W: Proliferation, survival and metabolism: The role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 143:3050–3060. 2016. View Article : Google Scholar : PubMed/NCBI
24	Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E and Wang L: PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 7:33440–33450. 2016.PubMed/NCBI
25	Wu L, Yang L, Xiong Y, Guo H, Shen X, Cheng Z, Zhang Y, Gao Z and Zhu X: Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells. Tumour Biol. 35:12327–12337. 2014. View Article : Google Scholar : PubMed/NCBI
26	Jin K, Li T, van Dam H, Zhou F and Zhang L: Molecular insights into tumour metastasis: Tracing the dominant events. J Pathol. Dec 30;2016Epub ahead of print. View Article : Google Scholar
27	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
28	Itoigawa Y, Harada N, Harada S, Katsura Y, Makino F, Ito J, Nurwidya F, Kato M, Takahashi F, Atsuta R, et al: TWEAK enhances TGF-β-induced epithelial-mesenchymal transition in human bronchial epithelial cells. Respir Res. 16:482015. View Article : Google Scholar
29	Kapral M, Wawszczyk J, Jurzak M, Dymitruk D and Weglarz L: Evaluation of the expression of metalloproteinases 2 and 9 and their tissue inhibitors in colon cancer cells treated with phytic acid. Acta Pol Pharm. 67:625–629. 2010.
30	Wang Q, Yu W, Huang T, Zhu Y and Huang C: RUNX2 promotes hepatocellular carcinoma cell migration and invasion by upregulating MMP9 expression. Oncol Rep. 36:2777–2784. 2016.PubMed/NCBI
31	Wu X, Tang Y, Huang W and Wu Y: Identification of proteins interacting with multidrug resistance protein in gastric cancer. World J Gastroenterol. 19:3568–3673. 2011.
32	Deng S, Wang J, Hou L, Li J, Chen G, Jing B, Zhang X and Yang Z: Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically. Oncol Lett. 5:107–112. 2013.